The Thyroid Trust shares the following research studies for information only and does not endorse them. All research studies are conducted by third party external sources from the charity so please contact them directly if interested.

Phase 2b clinical trial evaluating:
the safety and effectiveness of linsitinib in the treatment
​of active, ​moderate to severe Thyroid Eye Disease

Sling Therapeutics, Inc. is currently conducting a global Phase 2b clinical trial evaluating the safety and effectiveness of linsitinib, an insulin-like growth factor I receptor (IGF-1R) inhibitor, in the treatment of active, moderate to severe TED. The study medication is taken orally twice daily for 24 weeks.

Study-related care is provided at no cost, including the study medication. Travel expenses related to study visits will be reimbursed. 

To be eligible for this study, participants must:

• Be at least 18 years of age or older
• Have been told by a doctor that you have Thyroid Disease (E.g., hypothyroidism, hyperthyroidism, Grave’s disease or Hashimoto’s disease)
• Are experiencing one or more symptoms of Thyroid Eye Disease (bulging eyes, redness, irritation, swelling, and double or blurry vision)

To learn more about the study, please visit:
https://clinicaltrials.gov/ct2/show/NCT05276063

Inquiries to Sling Therapeutics can be directed to: 
info@slingtx.co​m

Interested participants may contact the following participating study sites in the UK:

Frimley Health Foundation Trust
Camberley, United Kingdom, GU16 7UJ
Contact: Elizabeth Baker       elizabeth.baker@nhs.net   

Cardiff University
Cardiff, United Kingdom, CF14 4XN
Contact: David Butler       David.Butler2@wales.nhs.uk   

Moorfields Eye Hospital NIHR Clinical Research Facility
London, United Kingdom, EC1V 2PD
Contact: Amanda Davis       amanda.davis5@nhs.net   ​

as of 06/04/23